Regorafenib, a novel oral multi-kinase inhibitor, disrupts kinases involved in tumor angiogenesis (VEGFR1, VEGFR2, VEGFR3, TIE2), tumorigenesis (KIT, RET, RAF1, BRAF, and BRAFV600E), and the tumor microenvironment (PDGFR and FGFR) (9). Here, FLT4 is linked to neoplasm.